Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)*
Major biologics to lose patent protection 2015-2020 by EU5 and U.S. revenue
This statistic shows the major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue, in billion euros. Adalimumab will lose its patent protection by 2018. This drug is generating over 10 billion euros of revenue annually. Biologicals which lose their patent protection are potentials for the biosimilars market.
Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)*
Revenue in billion euros
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

September 2016

Region

United States, EU

Survey time period

as of December 2015

Supplementary notes

* All sales figures are for MAT September 2015. EU-5 includes Germany, UK, France, Italy, and Spain.

Major biologics to lose patent protection 2015-2020 by EU5 and U.S. revenue
This statistic shows the major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue, in billion euros. Adalimumab will lose its patent protection by 2018. This drug is generating over 10 billion euros of revenue annually. Biologicals which lose their patent protection are potentials for the biosimilars market.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Statistics on "Pharmaceutical industry in Norway "
  • Overview
The most important statistics
  • Production and trade
  • Pharmaceutical turnover
  • R&D, patents and new products
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.